Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Anti-CD20 Antibody Therapy Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular and Diffuse Large B-Cell Lymphoma

NCT03401853 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT03401853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03401853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Anti-CD20 Antibody Therapy Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular and Diffuse Large B-Cell Lymphoma
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Terminated
Start date
March 23, 2018
Completion date
September 19, 2024
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent diffuse large b-cell lymphoma, recurrent follicular lymphoma, refractory diffuse large b-cell lymphoma, refractory follicular lymphoma